Prana Biotechnology's (PRAN) PBT2 treatment for Huntington disease met its primary endpoints of safety and tolerability in a Phase II study of 109 patients.
PBT2 also statistically improved executive function among early-stage Huntington's patients who received a 250 mg dose - but not the whole population - was associated with "a favorable signal in functional capacity" and a reduction atrophy of brain tissue.
However, the drug didn't bring about any significant improvements in other secondary efficacy measures in the study, including motor, functional and behavioral assessments.